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Knee Osteoarthritis in Obese Women With
Cardiometabolic Clustering
MARYFRAN SOWERS, CARRIE A. KARVONEN-GUTIERREZ, RIANN PALMIERI-SMITH,
JON A. JACOBSON, YEBIN JIANG, AND JAMES A. ASHTON-MILLER
Objective. To assess the role of obesity and metabolic dysfunctionality with knee osteoarthritis (OA), knee joint pain, and
physical functioning performance, adjusted for joint space width (JSW) asymmetry.
Methods. Knee OA was defined as a Kellgren/Lawrence score >2 on weight-bearing radiographs. Obesity was defined as
a body mass index >30 kg/m2. Cardiometabolic clustering classification was based on having >2 of the following factors:
low levels of high-density lipoprotein cholesterol; elevated levels of low-density lipoprotein cholesterol, triglycerides,
blood pressure, C-reactive protein, waist:hip ratio, or glucose; or diabetes mellitus. The difference between lateral and
medial knee JSW was used to determine joint space asymmetry.
Results. In a sample of women (n  482, mean age 47 years), prevalences of knee OA and persistent knee pain were 11%
and 30%, respectively. The knee OA prevalence in nonobese women without cardiometabolic clustering was 4.7%,
compared with 12.8% in obese women without cardiometabolic clustering and 23.2% in obese women with cardiometa-
bolic clustering. Nonobese women without cardiometabolic clustering were less likely to perceive themselves as limited
compared with women in all other obesity/cardiometabolic groups (P < 0.05). Similar associations were seen with knee
pain and physical functioning measures. The inclusion of a joint space asymmetry measure was associated with knee OA
but not with knee pain or physical functioning.
Conclusion. Knee OA was twice as frequent in obese women with cardiometabolic clustering compared with those
without, even when considering age and joint asymmetry. Obesity/cardiometabolic clustering was also associated with
persistent knee pain and impaired physical functioning.
INTRODUCTION
Osteoarthritis (OA), based on radiographs, is a highly prev-
alent joint disease affecting 30–50% of adults age 65
years (1,2). Age, female sex, obesity, and previous injury
are consistently reported risk factors for OA (3). Obesity is
the most conspicuous risk factor (4–7) and of great interest
because it is potentially modifiable. Further, there is con-
cern that with the increasing frequency of obesity, includ-
ing the escalating frequency of morbid obesity worldwide,
there will be an arthritis epidemic.
There is debate about how obesity contributes to the
initiation and progression of OA; resolution of this debate
could inform the selection of viable interventions. Candi-
date mechanisms for the contribution of obesity to joint
health status include 1) an excessive and/or misdirected
biomechanic load that stimulates excess osteoblast or
chondrocyte biosynthesis in the bone or cartilage (8); 2) a
generalized negative metabolic environment reflecting a
systemic inflammatory response (9–13) or response to the
secretory products of adipose tissues; or 3) both biome-
chanic and metabolic effects.
Hart and Spector (4) hypothesized that the association
between obesity and OA in non–weight-bearing joints in-
cludes a metabolic mechanism, but the data associating
OA with obesity-related metabolic factors are mixed. Some
studies have reported significant associations between
knee OA or hand/wrist OA and cardiovascular risk factors
(uric acid and cholesterol levels and hypertension) (10,11),
but other knee OA studies have failed to identify signifi-
cant relationships (12,13). Although some studies have
related higher concentrations of C-reactive protein to both
greater prevalence and incidence of knee OA (9,14,15), not
all studies have reported this (16,17).
The patterns (10,11,16,18) of association between meta-
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bolic factors and OA have led some to declare that the
primary contribution of obesity to OA may be joint specific
and dependent upon the degree to which obesity contrib-
utes to the mechanical loading of articular cartilage at a
specific site (19–21). For example, varus knee alignment is
thought to place mechanical loads, including those loads
generated by excess body mass, mostly on the medial
tibiofemoral compartment (22). The impact of excess body
mass at this site could generate both mechanical and met-
abolic contributions, whereas the impact of excess body
mass on hand OA may be more reflective of the metabolic
contribution.
We hypothesized that obesity was associated with both
a metabolic component and with joint asymmetry in rela-
tion to radiographic-defined knee OA. We also hypothe-
sized that these metabolic and biomechanic components
would be associated with knee joint pain and measures of
physical functioning.
SUBJECTS AND METHODS
Study population. The Michigan Bone Health and Me-
tabolism Study (MBHMS) is a longitudinal, population-
based study conducted among women living in and
around Tecumseh, Michigan. MBHMS enrollees were the
daughters of the Tecumseh Community Health Study par-
ticipants who, in 1988, were between the ages of 20 and 40
years, not pregnant, and premenopausal. These women
were contacted using letters, telephone calls, and in-per-
son visits, and 80% agreed to participate. In 1992, a
second sampling frame based on a community census of
Tecumseh was developed to include women whose par-
ents had not participated in the Tecumseh Community
Health Study. As a result, an additional 121 women in the
desired age range of 24–44 years (of a possible 135 eligi-
ble) were recruited (90% participation rate). The total
MBHMS cohort consists of 664 participants who were ages
24–44 years in 1992. All of the women in the MBHMS
cohort are white.
Although MBHMS participants have been followed an-
nually since 1992, this report is based on data that were
collected at MBHMS followup visit 11 (in 2002/2003).
Included in this report is followup visit 11 data from 482
MBHMS women with readable knee radiographs (to char-
acterize OA status), physical measures assessment and a
blood/urine sample for assay of cardiometabolites (to char-
acterize cardiometabolic obesity group), and performance-
based and self-reported physical functioning information.
The University of Michigan Institutional Review Board
approved the study protocol, and written informed con-
sent was obtained from each participant.
OA measures. Knee radiographs were taken using semi-
flexed positioning (23) with General Electric radiographic
equipment (model X-GE MPX-80; General Electric Medical
Systems, Milwaukee, WI) and Kodak film (X-DA with
Kodak rare earth-intensifying screens; Eastman Kodak,
Rochester, NY). The distance was 40 inches and standard
radiographic techniques were used. Radiographs were
evaluated by 2 readers, with a third consensus reader for
the presence of OA defined by the Kellgren/Lawrence
(K/L) scale depicted in the Atlas of Standard Radiographs
of Arthritis (where 0  normal, 1  doubtful OA, 2 
minimal OA, 3  moderate OA, and 4  severe OA) (24).
This scale is based on the degree of osteophyte formation,
joint space narrowing, sclerosis, and joint deformity. OA
was defined as the presence of 1 knee with a grade of 2.
Apart from the K/L criteria, joints were classified as unin-
terpretable, missing, or showing changes consistent with
rheumatoid arthritis.
As a part of the quality assurance program, readers re-
viewed the K/L grading criteria and evaluated films that
were representative of each K/L level. Then 25 knee radio-
graphs were evaluated independently by each reader and
their results were compared for consistency. After com-
pleting standardization procedures, readers indepen-
dently evaluated radiographs of both knees. The scores
from the 2 readers were compared and any discordant
scores were reread and, if necessary, subjected to consen-
sus evaluation. Further, a sample of 110 knee radiographs
selected for use in evaluations were interleaved with
newly acquired films to be reread to identify potential drift
in scoring over time.
Joint space width (JSW) was measured on the medial
and lateral aspects of each knee radiograph with electronic
calipers. Measurement locations were ascertained by iden-
tifying the centerline of each joint using the medial and
lateral tibial condyle margins and then establishing points
that were 50% and 75% between the centerline and the
condylar margin. Two readers measured the JSW indepen-
dently, and if the difference between the 2 readers was
0.4 mm, the JSW was remeasured by the 2 readers. The
absolute difference between the medial and lateral JSW at
the 75% location was used as a proxy of joint asymmetry.
Long films were not available to estimate the degree of
varus at the knee.
Pain and physical functioning measures. Pain and
physical functioning questionnaires are completed by
MBHMS participants. The pain questions ask if there has
been persistent knee joint pain during the antecedent 3
years and, if so, the participant is asked if there has been
pain at least half the time in the previous month.
The Medical Outcomes Study Short Form 36 (SF-36)
health survey 10-item physical function scale was used to
describe women’s perception of their physical functioning
limitations. This is a widely used questionnaire that has
been extensively evaluated for construct validity, internal
consistency, and test–retest reliability (25–28) in diverse
ethnic groups and age ranges. The SF-36 includes a 3-item
response (limited a lot, limited a little, or not limited at all)
to the following items: vigorous activities; moderate activ-
ities; lifting or carrying groceries; climbing several flights
of stairs; climbing 1 flight of stairs; bending, kneeling, or
stooping; walking 1 mile; walking several blocks; walk-
ing 1 block; or requiring assistance in bathing or dressing.
The SF-36 is scored using norm-based methods and trans-
formed to have a mean  SD of 50  10 and a range of
1–100 in the general US population, with a score of 100
indicating the best physical functioning. Scores were cat-
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egorized into 3 groups as follows: 50 points was classi-
fied as having substantial limitations, 51–85 points was
classified as having moderate limitations, and 86–100
points was classified as not limited. Women categorized as
having substantial limitations (50 points) could have
reported no limitations on, at most, 5 of the 10 activities.
Those classified as having moderate limitations (51–85
points) could have reported no limitations on, at most, 8 of
10 activities, thus allowing for some limitations in vigor-
ous and moderate activities.
Velocity assessment and timed 40-foot walk. Gait and
walking ability were assessed with a timed 40-foot walk,
measured in seconds, that included passage over an instru-
mented gait mat. The gait mat provided data to character-
ize velocity. The participants could walk with assistive
devices.
Sit-to-rise time. Chair-rise performance was measured
when participants rose from a standard height, armless
chair. Participants were asked to fold their arms over their
chest and to rise as quickly as possible. Movement time
was measured by stopwatch from the onset of trunk mo-
tion on the chair to the achievement of an upright standing
position. If a participant was unable to rise from the chair
or sat back down before achieving a full upright stance, the
rise was so noted. Results from 5 separate repetitions were
averaged.
Grip and leg strength. To measure grip strength, partic-
ipants were seated in a chair with their lower arm placed
at a right angle to the body’s sagittal plane with the elbow
in 90° of flexion. The hands were placed so that the fingers
and thumb were parallel to the legs and the wrist was
slightly extended to hold the dynamometer. Each partici-
pant performed 3 consecutive grip strength trials with both
the dominant and nondominant hands, squeezing the dy-
namometer with maximum effort. Results from the 3 trials
were averaged, and the participant’s average dominant
grip strength was used for analysis.
A portable instrumented chair was used to measure
lower leg isometric strength, measured as torque or the
product of force and the torque arm length. Torque arm
length is equal to the length measured between the lateral
joint line of the knee and the bottom surface of the heel
plus 0.0251 meters, which is the distance from the top
surface of the foot trolley platform to the transducer axis.
Participants were encouraged to produce maximum effort
for each trial, and the torque (in Nm) for 3 successful trials
was averaged.
Two-pound lift. Participants were timed as they lifted a
2-pound box from the floor to waist height. The box was
placed at a standard distance (8 inches) forward of the
toes. Participants could either bend at the knee or waist
and the modality was recorded. Inability to lift the box
successfully to waist height was flagged.
Timed stair climb. Each participant was asked to climb
up and down a set of 3 standard stairs 3 times, beginning
with the right leg. The amount of time that each partici-
pant required to ascend the stairs, turn, and descend the
stairs 3 consecutive times was measured for total move-
ment time (29). In addition, inability to complete the stair
climb (i.e., unable because of their use of a wheelchair)
and the amount and type of assistance needed (e.g., hand-
rails or a personal assistant) was recorded.
Functional reach. In the standing posture, participants
were asked to do an arm’s length forward reach, and then
to reach as far as possible without moving their feet. Par-
ticipants held a marking pen in their hand while doing the
arm’s length and forward reach, and placed a mark on a
sheet of paper with each reach. The distance between the
2 marks was measured to determine the forward reach
distance.
Cardiometabolic and body composition measures. Glu-
cose was measured using a hexokinase-coupled reaction
(Boehringer Mannheim Diagnostics, Indianapolis, IN). To-
tal cholesterol and triglycerides levels were analyzed by
enzymatic methods; high-density lipoprotein (HDL) cho-
lesterol level was isolated using heparin-2M manganese
chloride (30) and low-density lipoprotein (LDL) choles-
terol level calculated using the Friedewald equation (31).
High-sensitivity C-reactive protein level was measured us-
ing ultrasensitive rate immunonephelometry (Dade-
Behring, Marburg, Germany). Two blood pressure mea-
surements were taken using a mercury column manometer
after a minimum of 5 minutes of rest with participants in
the seated position, and the average of the 2 values was
used. Weight and height, measured with a calibrated bal-
ance beam scale and stadiometer, were used to calculate
body mass index (BMI; weight [kg]/height [m2]). Waist
circumference (in cm) was measured with a nonstretching
tape at the narrowest point of the midtorso at maximum
inhalation. Hip circumference was measured at a point 9
inches below the waist.
Women were classified into 1 of 4 cardiometabolic/obe-
sity subgroups based on their obesity status (nonobese:
BMI 30 kg/m2, or obese: BMI 30 kg/m2) and the pres-
ence or absence of 2 cardiometabolic defects, as de-
scribed in Table 1. Among those classified as having car-
diometabolic defects, obese women had greater numbers
of cardiometabolic defects, on average, as compared with
nonobese women.
Statistical analyses. Univariate distributions of the con-
tinuous measures of body size, metabolic products, JSW,
joint space difference, and physical functioning measures
were examined for normality. To meet the assumptions of
normality and to reduce skewness, natural log transforma-
tion was applied as necessary. The frequencies of the K/L
score for OA of the knee and categorical covariates, includ-
ing measures of pain and perception of physical function-
ing, were examined.
Knee K/L scores, pain, and measures of physical func-
tioning were the outcome measures, and variables repre-
senting obesity/cardiometabolic status and the difference
between the medial and lateral joint space were the ex-
planatory variables. P values for comparisons between
obesity/cardiometabolic groups or knee OA groups were
based on the nonparametric Wilcoxon’s signed rank test
for continuous variables or chi-square tests for categorical
variables. Analysis of variance and analysis of covariance
were used to determine the least squared means and SEs of
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groups defined by the combinations of the presence or
absence of knee OA/cardiometabolic group or physical
functioning/cardiometabolic group. Regression analyses
were used to evaluate the association of the difference in
JSW in models that also included variables for obesity/
cardiometabolic status and age. P values (2-sided tests)
and 95% confidence intervals (95% CIs) were used to
identify the likelihood of a true association.
RESULTS
The 2002 prevalence of radiographic-defined knee OA in
the MBHMS population was 11% and the prevalence of
having persistent knee pain during the previous 3 years
was 30%. Women with knee OA were 3 years older, 32%
heavier, and had more compromised metabolic measures
than women without knee OA, with the exception of LDL
cholesterol, for which there was no difference (Table 2).
The 2 nonobese groups with and without cardiometabolic
defects had significantly different median (interquartile
range [IQR]) BMI values (26.81 [3.72] kg/m2 and 23.76
[4.66] kg/m2, respectively; P  0.0001), but there were no
differences in the median (IQR) BMI values between the 2
obese groups with (34.82 [6.22] kg/m2) and without (32.97
[7.17] kg/m2) cardiometabolic defects (P  0.06).
Cardiometabolic clustering, obesity, and knee OA.
There was a higher knee OA prevalence in obese women
with cardiometabolic clustering (23.2%) compared with
the referent group of nonobese women without cardio-
metabolic clustering (4.7%), with an odds ratio (OR) of 6.2
(95% CI 2.93–13.07) (Table 3). Obese women without car-
diometabolic clustering had a knee OA prevalence of
12.8%; the OR of their having knee OA was 3.0 (95% CI
1.03–8.71) as compared with the referent group. Nonobese
women with cardiometabolic clustering did not have a
significantly greater OR of having knee OA than nonobese
women without cardiometabolic clustering.
Cardiometabolic clustering, obesity, and pain. Obese
women with cardiometabolic clustering reported signifi-
cantly more persistent knee pain during the previous 3
years (P  0.05) compared with women in the other 3
cardiometabolic/obesity groups (Table 4).
Table 1. Measures of cardiometabolic status
(participants with >2 criteria were classified
as having cardiometabolic defect)*
Measures
Self-reported DM, use of DM medications, or glucose
level 126 mg/dl†
CRP level 2 mg/liter‡
HDL cholesterol 45 mg/dl or LDL cholesterol 160
mg/dl§
Triglycerides 200 mg/dl‡
Waist:hip ratio 0.81 cm¶
Systolic BP 135 mm Hg, diastolic BP 85 mm Hg, or
use of high-BP medications#
* DM  diabetes mellitus; CRP  C-reactive protein; HDL  high-
density lipoprotein; LDL  low-density lipoprotein; BP  blood
pressure.
† Per the American Diabetes Association recommendation (32).
‡ Per the previously used cut point for elevated high-sensitivity
CRP level (33,34).
§ Per the Adult Treatment Panel III (ATP-III) recommendations (35)
for high/very high LDL cholesterol and high triglycerides. ATP-III
recommendations are for HDL cholesterol 40 mg/dl, but given
recent evidence of the importance of high HDL cholesterol values,
we chose a slightly higher cut point.
¶ Per the World Health Organization clinical risk categories of
waist:hip ratio (36).
# Values represent the upper end of the range considered prehyper-
tensive by the American Heart Association.
Table 2. Age, cardiometabolic factors, and JSW measurements in women with and
without radiographic-defined knee OA from MBHMS visit 11*
No knee OA (n  429) Knee OA (n  53) P†
Age, years 47.0 (8.0) 50.0 (5.0)  0.0001‡
Weight, kg 70.6 (23.2) 92.9 (24.8)  0.0001‡
BMI, kg/m2 27.3 (8.4) 35.6 (11.1)  0.0001‡
Waist:hip ratio, cm 0.81 (0.10) 0.86 (0.08) 0.0001‡
Glucose level, mg/dl 95.0 (13.0) 100.0 (14.0) 0.02‡
CRP level, mg/liter 0.19 (0.33) 0.33 (0.36) 0.002‡
Lipids levels, mg/dl
HDL cholesterol 54.0 (18.0) 49.0 (14.0) 0.03‡
LDL cholesterol 138.0 (45.0) 132.5 (43.0) 0.27
Triglycerides 117.0 (79.0) 141.0 (116.0) 0.01‡
BP, mm Hg
Systolic 117.5 (19.0) 126.0 (17.5)  0.0001‡
Diastolic 78.0 (12.0) 80.0 (9.0) 0.0004‡
JSW, mm
Medial 4.27 (1.02) 4.39 (1.27) 0.67
Lateral 5.55 (1.12) 6.28 (1.61)  0.0001‡
Difference 1.32 (1.11) 2.01 (1.81)  0.0001‡
* Values are the median (interquartile range). JSW  joint space width; OA  osteoarthritis; MBHMS 
Michigan Bone Health and Metabolism Study; BMI  body mass index; CRP  C-reactive protein; HDL 
high-density lipoprotein; LDL  low-density lipoprotein; BP  blood pressure.
† For between-group comparison.
‡ Significant (P  0.05).
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Cardiometabolic clustering, obesity, and physical func-
tioning. Nonobese women without cardiometabolic clus-
tering were significantly more likely to perceive them-
selves as not limited, based on the SF-36 physical
functioning score, compared with women in the other 3
categories (versus nonobese with cardiometabolic cluster-
ing P  0.004; versus obese without cardiometabolic clus-
tering P  0.03; versus obese with cardiometabolic clus-
tering P  0.0001). There were no differences in the
distribution of perception of limitation among women in
the other 3 cardiometabolic/obesity groups.
Obese women with cardiometabolic clustering had a
consistent 10% deficit in physical performance capacity
compared with nonobese women without cardiometabolic
clustering. Obese women with cardiometabolic clustering
had significantly greater stair climb times and 2-pound lift
times than those in any other category (Table 5). Among
nonobese women, those with cardiometabolic clustering
had significantly greater walk times and less gait velocity
than those without cardiometabolic clustering. Not sur-
prisingly, the obese women tended to have significantly
more quadriceps torque than those who were not obese.
The association of grip strength and obesity status varied
by cardiometabolic status (Table 6). Women with cardio-
metabolic clustering (both obese and nonobese groups)
had significantly shorter forward reach distances com-
pared with nonobese women without cardiometabolic
clustering.
Competitive modeling of biomechanic and metabolic
components. To examine the potential effect of obesity
generating biomechanic and metabolic components simul-
taneously, the statistical models included variables repre-
senting obesity/cardiometabolic status and the lateral–me-
dial JSW difference; all models were adjusted for age. Both
JSW difference and obesity/cardiometabolic status were
associated with knee OA. After adjustment for age, a 1-mm
increase in JSW difference was associated with 2.1 times
greater odds of having knee OA (95% CI 1.59–2.89), and
those who were obese with cardiometabolic clustering had
4.5 times greater odds of having knee OA (95% CI 1.88–
11.00) compared with the referent group of nonobese
women without cardiometabolic clustering.
Although obesity/cardiometabolic status was associated
with persistent knee joint pain, JSW difference was not.
Those who were obese with cardiometabolic clustering
had 2.5 times greater odds of having persistent knee pain
(95% CI 1.50–4.16) compared with the referent group. In
models of physical functioning, those who were obese
with cardiometabolic clustering consistently had signifi-
cantly poorer functioning, but there was no association
with the JSW difference measure (data not shown).
DISCUSSION
We identified obesity as being highly associated with ra-
diographic-defined knee OA, knee joint pain, perceived
physical functioning, and multiple measures of physical
functioning performance. However, although both OA and
obesity were highly prevalent in this sample, it is the
copresence of cardiometabolic clustering accompanying
obesity that exacerbates the association with radiographic-
defined knee OA, knee pain, and physical performance
measures. The presence of cardiometabolic clustering
among obese women is important because we identified
that the prevalence of knee OA was almost twice as great
in these women compared with obese women without
cardiometabolic clustering. Further, there was no signifi-
cant association of obesity in the pain measures or in many
of the physical functioning performance measures unless
Table 3. At MBHMS visit 11, the ORs (95% CIs) of
having knee OA (K/L score >2) according to the
presence or absence of cardiometabolic clustering






Nonobese (BMI 30 kg/m2)
Without clustering
(n  212)
10 (4.7) Reference group
With clustering
(n  85)
5 (5.9) 1.28 (0.43–3.87)
Obese (BMI 30 kg/m2)
Without clustering
(n  47)
6 (12.8) 3.00 (1.03–8.71)‡
With clustering
(n  138)
32 (23.2) 6.20 (2.93–13.07)§
* OR  odds ratio; 95% CI  95% confidence interval; K/L 
Kellgren/Lawrence. See Table 2 for additional definitions.
† From an unadjusted logistic regression model with the nonobese
without cardiometabolic clustering group as the referent category.
‡ P  0.05.
§ P  0.0001.
Table 4. At MBHMS visit 11, the number of women with persistent knee joint pain in the last 3 years and
knee pain in the last month, by obesity category and cardiometabolic clustering*
Knee joint pain









Persistent during last 3 years 47 (22.2)† 24 (28.2)† 12 (25.5)† 60 (43.5)
If yes, present during half of last month 34 (16.0) 17 (20.0) 6 (13.0) 49 (35.5)
* Values are the number (percentage). See Table 2 for definitions.
† Value is significantly different than for those who are obese with cardiometabolic clustering (P  0.05). No other pairwise differences were
statistically significant.
1332 Sowers et al
obesity was accompanied by cardiometabolic clustering.
The presence of the same patterns of association of obesity
with cardiometabolic clustering in relation to pain and
physical performance suggests that there is internal valid-
ity in this association.
It is important to note, however, that being obese is not
synonymous with the clustering of cardiometabolic risk
factors. Of obese women in this sample, 25% did not have
cardiometabolic clustering. Likewise, we have previously
reported that approximately one-third of obese men and
women of the Third National Health and Nutrition Exam-
ination Survey sample, representative of the US popula-
tion, did not have evidence of cardiometabolic clustering
(37).
There is substantial opportunity for obesity to have a
physiologic role in the development and subsequent pro-
gression of knee OA. Recognition of the potential for this
key role has emerged over the past 10 years with the
understanding that adipose tissue secretes hormones with
receptor-mediated action similar to other endocrine or-
gans. We hypothesize that the observed relationship be-
tween cardiometabolic abnormalities and obesity is a re-
flection of the relationships between products secreted by
adipose tissue and cardiovascular disease risk factors. We
have published data (38) from a subset of this population
in which greater increases in leptin over the menopause
transition were associated with greater decreases in HDL
cholesterol, and with greater increases in diastolic blood
pressure, glucose, insulin, and insulin resistance (all P 
0.05). Larger decreases in adiponectin over the menopause
transition were associated with greater increases in sys-
tolic blood pressure, insulin, and insulin resistance, and
with greater decreases in HDL cholesterol.
Leptin, encoded by the obesity gene (39) to reduce food
intake and increase energy expenditure (40), thereby indi-
rectly mediating body fat stores (41), was initially thought
to be limited to the adipocytes, but it has been shown that
osteoblasts and chondrocytes are capable of leptin synthe-
sis and secretion (41,42), and leptin receptors have been
found in articular cartilage (43). Leptin concentrations
Table 5. At MBHMS visit 11, the participants in SF-36 physical functioning categories
by obesity category and cardiometabolic clustering*
SF-36 physical
functioning category









Not limited 171 80.7† 53 62.4 29 61.7 71 51.5
Moderately limited 36 17.0 27 31.8 16 34.0 53 38.4
Substantially limited 5 2.4 5 5.9 2 4.3 14 10.1
* Values are the percentage. SF-36  Short Form 36 health survey. See Table 2 for additional definitions.
† Value is significantly different than for those in the other 3 cardiometabolic obesity categories (P  0.05).
Table 6. At Michigan Bone Health and Metabolism Study visit 11, mean  SE values (back-transformed) for performance-
based physical functioning by obesity and cardiometabolic status
Nonobese
(body mass index <30 kg/m2)
Obese







Timed stair climb, seconds 15.80  0.21 16.26  0.35 16.36  0.46§ 18.10  0.30¶ 0.0001
Timed walk, seconds 7.94  0.07# 8.26  0.11** 8.24  0.15 8.58  0.09# 0.0001
Velocity, cm/second 174.03  1.65¶ 167.64  2.46** 164.45  3.36** 159.70  1.90# 0.0001
2-pound lift, seconds 1.58  0.03 1.61  0.04 1.58  0.05§ 1.74  0.04¶ 0.001
Quadriceps strength/average
torque, Nm
71.59  1.61†† 68.81  2.41†† 84.82  4.06‡‡ 80.77  2.22# 0.0001
Grip strength, kg 26.13  0.52# 23.46  0.74** 25.92  1.09 26.42  0.66# 0.02
Forward reach, cm 34.87  0.42# 32.98  0.63** 34.54  0.87 33.18  0.49 0.02
Sit-to-rise time, seconds 1.00  0.02 0.99  0.03 1.01  0.04 1.08  0.03 0.06
* All means are significantly different (P  0.05) than the means for the obese with cardiometabolic clustering, except for grip strength and sit-to-rise
time.
† All means are significantly different (P  0.05) than the means for the obese with cardiometabolic clustering, except for forward reach and sit-to-rise
time.
‡ All means are significantly different (P  0.05) than the means for the nonobese without cardiometabolic clustering, except for grip strength and
sit-to-rise time.
§ Mean is significantly different (P  0.05) than the mean for the obese with cardiometabolic clustering.
¶ Mean is significantly different (P  0.05) than the means for the nonobese with and the obese without cardiometabolic clustering.
# Mean is significantly different (P  0.05) than the mean for the nonobese with cardiometabolic clustering.
** Mean is significantly different (P 0.05) than the mean for the nonobese without cardiometabolic clustering.
†† Mean is significantly different (P  0.05) than the mean for the obese without cardiometabolic clustering.
‡‡ Mean is significantly different (P  0.05) than the means for the nonobese with and the nonobese without cardiometabolic clustering.
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found in the synovial fluid of people with OA correlated
with their BMI. In animal models, leptin stimulated ana-
bolic activity in chondrocytes, including induction of in-
sulin-like growth factor 1 (IGF-1) and transforming growth
factor  (TGF) synthesis at both the messenger RNA and
protein levels. IGF-1 and TGF are activated in response to
cartilage damage (44–46), and the anabolic activity of
chondrocytes serves as a repair mechanism for damaged
cartilage.
Levels of adiponectin, an adipokine associated with in-
sulin sensitivity regulation (47,48), are low in obese indi-
viduals and in those with cardiovascular disease. Adi-
ponectin is present in the synovial fluid (49,50), cartilage,
osteophytes, infrapatellar fat pad, and menisci (51,52) of
OA patients, and functional adiponectin receptors have
been expressed in chondrocytes (53).
Because of the decreased levels of adiponectin among
those with cardiovascular disease, adiponectin has been
hypothesized to have antiinflammatory effects (47); how-
ever, recent work among those with joint diseases suggests
that adiponectin may, in fact, have proinflammatory ef-
fects and be involved with cartilage matrix degradation
(53–55). Lago et al (53) recently demonstrated that adi-
ponectin induced the expression of type 2 nitric oxide
synthase and stimulated interleukin-6, matrix metallopro-
teinase 3 (MMP-3), MMP-9, and monocyte chemotactic
protein 1 release.
As has been recently reviewed, the additional loading
associated with obesity is almost universally believed to
produce aberrant mechanics, raising stress within connec-
tive tissue structures, generating malalignment, and result-
ing in musculoskeletal injury (56). There are numerous
mechanical theories as to how obesity can impact move-
ment, but the evidence directly linking musculoskeletal
injury to altered biomechanics in the obese is not exten-
sive. It is thought that obesity leads to both increased
gravitational and muscle forces across the knee joint, and
that once cartilage degradation is present, knee OA
progresses more rapidly in the presence of larger-than-
normal knee loads during gait (22). Further, Messier et al
(57) reported that the peak vertical ground-reaction forces
increased in almost direct proportion with body weight in
obese adults who were walking. Recent work by Browning
and Kram in young adults (58) demonstrated that net mus-
cle moments were significantly greater in obese versus
normal-weight subjects and were due to greater ground-
reaction forces in the obese group. Obesity greatly in-
creases the biomechanic loads involved in walking, a fre-
quently proposed therapy for obesity, and these loads
increase with walking speed.
BMI has been related to knee OA severity in those with
varus knees but not in those with valgus knees (59). Al-
though those investigators concluded that much of the
effect of BMI on the severity of medial tibiofemoral OA
was explained by varus malalignment, the investigators
statistically controlled for sex rather than reporting the
association stratified by sex. The impact of obesity on the
alignment of the tibiofemoral compartment may be differ-
ent in men versus women because of the inherent sex
difference in pelvic alignment.
We found that our proxy measure of tibiofemoral joint
asymmetry (the difference between lateral and medial
JSW) was significantly associated with having knee OA as
a main effect concurrently with cardiometabolic status as a
main effect. Interestingly, however, knee joint asymmetry
was not associated with pain or physical functioning mea-
sures, whereas obesity/cardiometabolic status was asso-
ciated with more pain and poorer physical functioning.
This may have occurred because this joint asymmetry
proxy measure was directly associated with radiographic-
defined OA, and was only indirectly associated with the
pain and functioning measures.
This study had several strengths and limitations. The
study included a direct measure of radiographic-defined
knee OA along with measures of persistent knee pain and
physical performance/functioning. Further, because this
population-based sample is limited to women, our find-
ings were not complicated by the increasing evidence of
the differences in body composition and cardiometabolic
measures between men and women. Therefore, our find-
ings may have a greater impact on women, the group that
is at the greatest risk for knee OA. Likewise, the restricted
age of our population (60 years of age) allowed us to
minimize the effects of aging, the primary risk factor for
knee OA, on the cardiometabolic results. Nevertheless, the
impact of cardiometabolic obesity and tibiofemoral joint
asymmetry in those 60 years of age is yet to be revealed.
The major limitation of our study is that it did not include
long films to assess varus alignment, and so we relied
instead upon a proxy joint asymmetry measure, the differ-
ence between medial and lateral joint space.
We hypothesized that obesity was associated with both
metabolic and biomechanic alignment in relation to radio-
graphic-defined OA of the knee. We also hypothesized that
these metabolic and biomechanic components would be
associated with knee joint pain and measures of physical
functioning. Although obesity was strongly associated
with knee OA, the most prominent associations with knee
OA, pain, or functioning occurred when obese women also
demonstrated clustering of cardiometabolic patterning.
This observation has important ramifications for the selec-
tion of both behavioral and therapeutic treatments of knee
OA.
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